AC Immune’s (ACIU) Buy Rating Reiterated at BTIG Research

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating reiterated by equities researchers at BTIG Research in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $8.00 price objective on the stock. BTIG Research’s price target indicates a potential upside of 246.62% from the stock’s previous close.

A number of other equities research analysts have also weighed in on ACIU. HC Wainwright reissued a “buy” rating on shares of AC Immune in a report on Wednesday, July 1st. Weiss Ratings cut shares of AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 8th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $7.50.

AC Immune Price Performance

Shares of ACIU traded up $0.04 during trading hours on Wednesday, reaching $2.31. The stock had a trading volume of 124,874 shares, compared to its average volume of 291,611. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.02 and a current ratio of 0.87. AC Immune has a 12 month low of $2.03 and a 12 month high of $4.00. The stock has a market capitalization of $234.89 million, a PE ratio of -2.81 and a beta of 1.59. The company’s 50-day moving average is $2.39 and its two-hundred day moving average is $2.79.

AC Immune (NASDAQ:ACIU) last issued its earnings results on Wednesday, August 5th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.09). AC Immune had a negative return on equity of 125.26% and a negative net margin of 1,788.02%.The firm had revenue of $18.67 million during the quarter, compared to analyst estimates of $34.08 million. Research analysts expect that AC Immune will post -0.84 EPS for the current year.

Insider Activity at AC Immune

In other news, CEO Andrea Pfeifer sold 10,000 shares of the stock in a transaction on Friday, May 15th. The shares were sold at an average price of $2.79, for a total transaction of $27,900.00. Following the completion of the sale, the chief executive officer directly owned 3,820,288 shares in the company, valued at $10,658,603.52. This represents a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. EFG International AG acquired a new position in shares of AC Immune in the 4th quarter valued at about $41,000. Private Advisor Group LLC acquired a new position in AC Immune in the third quarter valued at approximately $48,000. Sei Investments Co. bought a new position in shares of AC Immune during the 2nd quarter worth approximately $51,000. Goldman Sachs Group Inc. grew its position in shares of AC Immune by 46.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock worth $58,000 after buying an additional 5,920 shares during the period. Finally, Susquehanna International Group LLP bought a new stake in shares of AC Immune in the 3rd quarter valued at $63,000. 51.36% of the stock is owned by institutional investors.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.